Downregulated CAV-1 in Mouse Spinal Cord May Alleviate Bone Cancer Pain by Inhibiting the ERK/CREB Pathway.

Jianyun Ge,Jie Song,Bo Sun,Xuefeng Yang,Boxiang Du,Xin Sun,Jiejie Zhang,Jianlin Ge,Hong Xie
DOI: https://doi.org/10.1016/j.mrfmmm.2023.111829
2023-01-01
Mutation Research
Abstract:BACKGROUND:This study aimed to assess the potential function of Caveolin-1 (CAV-1) in mice with bone cancer pain.METHOD:Using a mice bone cancer pain model we explored the contribution of CAV-1 expression to bone cancer pain on the 14th day after surgery, mice in the tumor group were randomized and treated with increasing doses of the CAV-1 inhibitor, methyl-beta-cyclodextrin. Pain was assessed by monitoring the number of spontaneous flinches (NSF) and paw withdrawal mechanical threshold (PMWT)mechanical withdrawal threshold (MWT). The localization and expression of CAV-1 in mouse neurons was also determined. Additionally, the protein levels of CAV-1, extracellular signal regulated kinase (ERK) 1/2, cAMP response element-binding protein (CREB) were monitored in mouse spinal cord tissues by western blotting.RESULTS:CAV-1 was remarkably upregulated in the spinal cord of the tumor group on the 4th day after surgery, then downregulated on day 10, and upregulated again at day 14. Such CAV-1 levels were maintained until day 28. In the tumor group, the expression of p-ERK1/2 and p-CERB were upregulated at day 14 after surgery. Intrathecal injection of methyl-beta-cyclodextrin (MCD) downregulated p-ERK1/2 and p-CERB expression which correlated with alleviation of pain.CONCLUSION:Inhibition of CAV-1 in the spinal cord alleviates bone cancer pain in mice which correlates with inhibition of the ERK/CREB pathway.
What problem does this paper attempt to address?